Evaxion Biotecch (EVAX)
(Delayed Data from NSDQ)
$3.15 USD
-0.15 (-4.57%)
Updated Jul 15, 2024 03:58 PM ET
After-Market: $3.09 -0.06 (-1.88%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EVAX 3.15 -0.15(-4.57%)
Will EVAX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EVAX
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
EVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study
Bears are Losing Control Over Evaxion Biotech AS Sponsored ADR (EVAX), Here's Why It's a 'Buy' Now
Other News for EVAX
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
Evaxion Biotech’s Innovative Cancer Vaccine Patent Progress
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
Evaxion receives positive feedback on patent application for vaccine targets
Evaxion Biotech Updates Warrant Exercise Price